The study found that the noise of the aircraft caused damage to myocardial infarction

Published Date: 17 Feb 2023

Noise can play an important role in the initiation and progression of ischemic heart disease. Researchers from the Department of Cardiology at the University Medical Center Mainz have found that noise exposure...

Read Full News

Latest News

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP

Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class Linda Stein Gold, MD, Andrew Blauvelt, MD

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD Eric Simpson, MD, MCR

Simpson discusses 16-week phase 2 data on the IL-4/IL-13/TSLP trispecific, including vIGA gaps and conjunctivitis findings.

Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD Aaron R. Mangold, MD

Aaron Mangold, MD, discusses phase 2 BEACON data on brepocitinib, a TYK2/JAK1 inhibitor, in cutaneous sarcoidosis presented at EADV 2026.

Todays Updates

Why Oxygen Stigma Persists, With Mike Hess, MPH Mike Hess, MPH

On World Oxygen Day, the COPD Foundation's Mike Hess outlines the stigma, training gaps, and Medicare barriers affecting patients on supplemental oxygen.

When to Switch Biologics in Severe Asthma, With Florence Schleich, MD, PhD Florence Schleich, MD, PhD

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Lower Baseline FVC Linked to Better Sarcoidosis Treatment Response Vivienne Kahlmann

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

Vanzacaftor Regimen Lets Some Children With Cystic Fibrosis Stop PERT

Vanzacaftor Regimen Lets Some Children With Cystic Fibrosis Stop PERT

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Real-World Data Back Stiripentol’s Effect on Seizures in Dravet Syndrome Marco Meglio

A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.

Diazepam Nasal Spray Terminates Most Pediatric Status Epilepticus Episodes in Seizure Clusters, Post Hoc Analysis Shows Isabella Ciccone, MPH

Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.

Todays Updates

Why Oxygen Stigma Persists, With Mike Hess, MPH Mike Hess, MPH

On World Oxygen Day, the COPD Foundation's Mike Hess outlines the stigma, training gaps, and Medicare barriers affecting patients on supplemental oxygen.

When to Switch Biologics in Severe Asthma, With Florence Schleich, MD, PhD Florence Schleich, MD, PhD

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Lower Baseline FVC Linked to Better Sarcoidosis Treatment Response Vivienne Kahlmann

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

Vanzacaftor Regimen Lets Some Children With Cystic Fibrosis Stop PERT

Vanzacaftor Regimen Lets Some Children With Cystic Fibrosis Stop PERT

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Real-World Data Back Stiripentol’s Effect on Seizures in Dravet Syndrome Marco Meglio

A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.

Diazepam Nasal Spray Terminates Most Pediatric Status Epilepticus Episodes in Seizure Clusters, Post Hoc Analysis Shows Isabella Ciccone, MPH

Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.

Latest News

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Simpson discusses 16-week phase 2 data on the IL-4/IL-13/TSLP trispecific, including vIGA gaps and conjunctivitis findings.

Aaron Mangold, MD, discusses phase 2 BEACON data on brepocitinib, a TYK2/JAK1 inhibitor, in cutaneous sarcoidosis presented at EADV 2026.

News All Time

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Conference Preview: Fall Clinical Dermatology Conference 2026

Conference Preview: Fall Clinical Dermatology Conference 2026

Tips on Optimizing HS Biologics, Combinations, and Surgery

Tips on Optimizing HS Biologics, Combinations, and Surgery

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Patient Perspective on Topical Steroid Withdrawal, With Briana Banos Briana Banos

Topical steroid withdrawal advocate Briana Banos urged clinicians to stay curious and treat patients as experts on their own bodies.

Corticosteroid Stewardship in Dermatology is Not Steroid Avoidance, With Adam Friedman, MD Adam Friedman, MD, FAAD

Friedman outlines how dermatologists can track cumulative corticosteroid exposure, identify at-risk patients, and improve patient adherence with handouts.

Recommended News For You

Significant worldwide disparities seen in availability and timeliness of new cancer drugs

Experts say oncology, primary care coordination necessary for best cancer patient outcomes

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

Appropriate New Monoclonal for Immunocompromised Individuals to Prevent COVID-19.

Race, Geography Linked to Gaps in Prostate Cancer Care

Slowdown in progress found with cancer survival in England and Wales

FDA Approves First Menin Inhibitor for Acute Leukemia

Recommended Articles For You

Molecular Matching for Individualized Blood-Disorder Therapy 

Remote Hematology Consultation Networks: Transforming Access and Delivery of Specialist Care 

Ear Emergency: Understanding the Causes and Treatment for Auricular Hematoma 

Anion Gap: The Simple Calculation That Reveals Much About Your Health  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reducing social media to an hour a day boosts young people's self-image.

2.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

3.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

4.

A prostate cancer risk prediction algorithm could help target men at highest risk

5.

FDA Approves Iberdomide Combo for Multiple Myeloma

1.

Altered Marrow Cell-Production Dynamics During Chronic Hematologic Stress

2.

Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome

3.

Personalized Cancer Vaccines: The Next Frontier in Precision Oncology

4.

Surgical Innovation Using Hematopoietic Reserve Preservation During Major Surgery

5.

The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V

2.

Understanding the Common Causes of Anemia

3.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

4.

Thromboprophylaxis In Medical Settings- An Update

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot